Why it matters: The report highlights the widespread use of cannabis in Europe and the associated problems faced by consumers. It also sheds light on the availability of various cannabis products, including high-potency extracts and edibles, which have been linked to acute toxicity cases. The increasing demand for cannabis products is evident from the high number of people entering drug treatment programs and the record-breaking seizures of cannabis products.
What they are saying: The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) report reveals that cannabis is the most commonly consumed illicit drug in Europe. It states that 8% of European adults have used cannabis in the past year, with 1.3% being daily or almost daily consumers. The report also addresses the availability and consumption preferences of cannabis products, with a significant percentage of users opting for resin, edibles, and extracts.
The big picture: The popularity of cannabis in Europe has led to an increase in consumer problems, such as dependence or addiction. The availability of high-potency extracts and edibles is a particular concern, as they have been linked to acute toxicity cases. The report also highlights the rise of synthetic cannabinoids, such as hexahydrocannabinol, in certain EU countries. However, some EU countries are taking steps towards legalization to regulate the market and mitigate the black market’s influence.
What to watch: It will be important to monitor the impact of cannabis legalization efforts in EU countries. The regulatory frameworks being developed, such as non-profit social clubs in Germany, could shape the future of cannabis consumption in these countries. Additionally, continued research and monitoring of the health and social effects of regulated cannabis, as seen in Switzerland’s pilot programs, can provide valuable insights into harm reduction approaches and strict controls on supply and distribution.
My take: The widespread use of cannabis in Europe and the associated problems underscore the need for comprehensive understanding, regulation, and harm reduction measures. As cannabis becomes increasingly available in various forms, it is crucial to address the potential risks and ensure access to appropriate treatment options. Legalization efforts across EU countries can offer a regulated market that prioritizes consumer safety and undermines the black market’s influence. Research and pilot programs, like those in Switzerland, can contribute to evidence-based approaches for managing cannabis use and its effects.
